Cargando…

The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer

BACKGROUND: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa). MATERIAL AND METHODS: Within the Surveillance, Epid...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenzel, Mike, Nocera, Luigi, Würnschimmel, Christoph, Collà Ruvolo, Claudia, Tian, Zhe, Saad, Fred, Briganti, Alberto, Tilki, Derya, Graefen, Markus, Becker, Andreas, Roos, Frederik C., Chun, Felix K. H., Karakiewicz, Pierre I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526938/
https://www.ncbi.nlm.nih.gov/pubmed/34692543
http://dx.doi.org/10.3389/fonc.2021.754996
_version_ 1784585972126580736
author Wenzel, Mike
Nocera, Luigi
Würnschimmel, Christoph
Collà Ruvolo, Claudia
Tian, Zhe
Saad, Fred
Briganti, Alberto
Tilki, Derya
Graefen, Markus
Becker, Andreas
Roos, Frederik C.
Chun, Felix K. H.
Karakiewicz, Pierre I.
author_facet Wenzel, Mike
Nocera, Luigi
Würnschimmel, Christoph
Collà Ruvolo, Claudia
Tian, Zhe
Saad, Fred
Briganti, Alberto
Tilki, Derya
Graefen, Markus
Becker, Andreas
Roos, Frederik C.
Chun, Felix K. H.
Karakiewicz, Pierre I.
author_sort Wenzel, Mike
collection PubMed
description BACKGROUND: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa). MATERIAL AND METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004–2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses. RESULTS: We identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa. CONCLUSION: Patients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis.
format Online
Article
Text
id pubmed-8526938
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85269382021-10-21 The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer Wenzel, Mike Nocera, Luigi Würnschimmel, Christoph Collà Ruvolo, Claudia Tian, Zhe Saad, Fred Briganti, Alberto Tilki, Derya Graefen, Markus Becker, Andreas Roos, Frederik C. Chun, Felix K. H. Karakiewicz, Pierre I. Front Oncol Oncology BACKGROUND: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa). MATERIAL AND METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004–2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses. RESULTS: We identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa. CONCLUSION: Patients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis. Frontiers Media S.A. 2021-10-06 /pmc/articles/PMC8526938/ /pubmed/34692543 http://dx.doi.org/10.3389/fonc.2021.754996 Text en Copyright © 2021 Wenzel, Nocera, Würnschimmel, Collà Ruvolo, Tian, Saad, Briganti, Tilki, Graefen, Becker, Roos, Chun and Karakiewicz https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wenzel, Mike
Nocera, Luigi
Würnschimmel, Christoph
Collà Ruvolo, Claudia
Tian, Zhe
Saad, Fred
Briganti, Alberto
Tilki, Derya
Graefen, Markus
Becker, Andreas
Roos, Frederik C.
Chun, Felix K. H.
Karakiewicz, Pierre I.
The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
title The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
title_full The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
title_fullStr The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
title_full_unstemmed The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
title_short The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
title_sort effect of 10 most common nonurological primary cancers on survival in men with secondary prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526938/
https://www.ncbi.nlm.nih.gov/pubmed/34692543
http://dx.doi.org/10.3389/fonc.2021.754996
work_keys_str_mv AT wenzelmike theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT noceraluigi theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT wurnschimmelchristoph theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT collaruvoloclaudia theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT tianzhe theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT saadfred theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT brigantialberto theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT tilkiderya theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT graefenmarkus theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT beckerandreas theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT roosfrederikc theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT chunfelixkh theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT karakiewiczpierrei theeffectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT wenzelmike effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT noceraluigi effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT wurnschimmelchristoph effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT collaruvoloclaudia effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT tianzhe effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT saadfred effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT brigantialberto effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT tilkiderya effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT graefenmarkus effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT beckerandreas effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT roosfrederikc effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT chunfelixkh effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer
AT karakiewiczpierrei effectof10mostcommonnonurologicalprimarycancersonsurvivalinmenwithsecondaryprostatecancer